Why Accelerate Diagnostics (AXDX) Stock Is Down 38%

Accelerate Diagnostics, Inc. AXDX shares are trading lower by 38% to $1.00 during Friday’s session after the company priced an underwritten public offering of 6,860,659 units at $1.50 each, comprising a share of common stock and a warrant.

What Else?

The underwriters have an option for an additional 1,029,098 shares and/or warrants. Warrants are exercisable at $1.65 per share, pre-funded warrants at $0.01 per share, both valid for five years. Gross proceeds are expected to be $10.3 million.

Concurrently, a private placement to the Jack W. Schuler Living Trust involves the sale of 1,156,069 units at $1.73 per unit, with an agreement for an additional 1,560,693 units. Gross proceeds from the private placement are expected to be $4.7 million.

The public offering is set to close around January 23, subject to customary conditions. William Blair & Company, L.L.C. is the sole book-running manager, and Craig-Hallum Capital Group LLC is the co-manager.

See Also: Fed's Goolsbee Expects Interest Rates To Fall With Inflation

According to data from Benzinga Pro, AXDX has a 52-week high of $11.90 and a 52-week low of $0.95.